JASN Podcast cover art

All Episodes

JASN Podcast — 83 episodes

#
Title
1

Subclinical Primary Aldosteronism and eGFR Decline

2

ASN Kidney Translation Series: Peritoneal Dialysis

3

PD Use in Health Service Areas, 2009–2020

4

ASN Kidney Translation Series: ASN Kidney Health Guidance on Conservative Management in People with Kidney Failure

5

LCN2-Induced CLUH Inhibition Disrupts Mitochondria in Kidney

6

ASN Kidney Translation Series: Kidney Transplant Advances

7

Automatic Organ and Cyst Volumes in ADPKD

8

Coronary Disease Screening Prior to Kidney Transplant

9

ASN Kidney Translation Series: Advances in Glomerular Filtration Rate

10

Bone Marrow Inflammation Drives Glomerular Damage

11

ICD Code Accuracy for CVD in CKD

12

Dapagliflozin and HRQoL in Patients with CKD

13

ASN Kidney Translation Series: Glomerulonephritis

14

RNA Sequencing of IgA Nephropathy Kidneys

15

Alternative Splicing and Polyadenylation in Glomerular Disease

16

The PEER-HD Randomized Controlled Trial

17

SGLT2 Inhibitors and Risk of Urinary Tract Infections with Abnormal Genitourinary Pathology

18

Disaster Management in Kidney Care

19

Regulation of Renal Glucose Handling by mTORC2

20

Drug Screening in Drosophila Nephrocytes

21

ASN Kidney Translation Series: ADPKD Advances

22

Anticoagulation in Dialysis Recipients with Atrial Fibrillation

23

CASR Determines Renal Response to Hypercalcemia

24

ASN Kidney Translation Series: ASN Kidney Health Guidance on the Outpatient Management of Patients with Dialysis-Requiring Acute Kidney Injury

25

ASN Kidney Translation Series: Kidney Stones

26

Molecular Signature of NPCs in the Catshark

27

Acetazolamide and the Kidney in T1D

28

Kidney Protection by Acetylcholine

29

ASN Kidney Translation Series: Genetic Testing in Nephrology

30

ASN Kidney Translation Series: Novel Therapies for IgA Nephropathy

31

Polycystin-2 Regulates Natriuretic Peptide Production

32

ASN Kidney Translation Series: ASN Kidney Health Guidance on the Management of Obesity in Persons Living with Kidney Diseases

33

KLF15 Agonist in Kidney Disease

34

Stem Cells in Renovascular Disease

35

ASN Kidney Translation Series: Gender Equity in Nephrology

36

Tubular Effect of Proteinuria

37

sGC Activator Avenciguat for CKD

38

Absolute CKD Progression Risk

39

Set7 Regulates Glomerular Injury

40

ASN Kidney Translation Series: PPI, Antivirals, and Cough Syrups: Nephrotoxins and Kidney Injury

41

Daprodustat and Heart Failure in CKD

42

Changes in ESKD Incidence

43

The Final JASN Podcast

44

SGLT2 Inhibitors and Continuation of Renin Angiotensin Blockade

45

Kidney Transplant Registry Data: Advice for Users

46

Historical Redlining and the Incidence of Kidney Failure in US Cities

47

Next Steps in Development of Mesenchymal Stem Cells as Possible Therapeutic for Kidney Disease

48

Antibiotic Use & Kidney Stones and Sodium Bicarbonate & the Vascular Dysfunction of CKD

49

How Many Nephrons in a Human Kidney? A New Number and a Discussion of Why it Matters

50

The Angiopoietin-Tie 2 Pathway is Ischemic Kidney Injury

51

Urea and Uremia

52

Use of Kidney Organoids to Study Steroid-Resistant Nephrotic Syndrome

53

A Conversation with Deidre Crews and Tanjala Purnell about COVID-19, Structural Racism and Kidney Disease

54

A Discussion with Andrew Malone and Madhav Menon: RNAseq and the Transplant Biopsy, What is New?

55

A Dialogue with Mahboob Rahman and Erin Barreto About Ambulatory Blood Pressure Monitoring in Patients with Chronic Kidney Disease

56

A Conversation with Mark Knepper and Josie Briggs: Does SARS-CoV2 Infect the Kidney?

57

JASN January 2021 Issue Highlights

58

JASN February 2021 Issue Highlights

59

JASN March 2021 Issue Highlights

60

JASN April 2021 Issue Highlights

61

JASN May 2022 Issue Highlights

62

New Insights into the Mechanisms of Kidney Disease: Understanding Hypercholesterolemia in CKD; ADAM10 and Immune Injury to the Podocyte Slit Diaphragm

63

COVID-19 Mortality and the Tough Discussions about Advance Care Planning

64

Vaccine Acceptability and Hemodialysis Patients

65

The Extracellular Matrix in Development, Aging, and Disease

66

Lost Opportunities for Kidney Transplant

67

JASN August 2021 Issue Highlights

68

New Directions for Clinical Trials in Kidney Disease

69

JASN October 2021 Issue Highlights

70

JASN November 2021 Issue Highlights

71

The Immune Responses to COVID-19 in Transplant Patients

72

Insights into Collapsing Glomerulopathy

73

Lowering GFR to Protect GFR!

74

The Renal Framingham - CVD Prediction

75

Roxadustat and the Interpretation of Non-Inferiority

76

JASN May 2022 Highlights: Inflammation as a Driver of CKD Progression

77

A New Approach to Advance Care Planning for Dialysis Decisions: Deciding not to Decide

78

Discontinuing Immunosuppressant Use after Allograft Failure: Do We Have the Answers?

79

Addressing Racial and Ethnic Disparities in Kidney Disease

80

August 2022 JASN Highlights: Addressing CKD Progression and Hazards of Intradialytic Hypotension

81

Climate Change: Implications for Nephrology

82

Gender Differences in Care of CKD Patients

83

Comparing Costs of Hemodialysis and Peritoneal Dialysis